WEST PHARMACEUTICAL SERVICES INC (WST)

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read WEST PHARMACEUTICAL SERVICES INC's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper WST reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

One page per director: the seat, the committees and the fee table, read for one person at a time.

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Our executive compensation philosophy centers on providing competitive executive pay opportunities that support both short-term performance and long-term success. We use a market median target compensation approach, evaluating each compensation component (base salary, target annual incentive compensation and long-term incentive compensation) against the market median.

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

a. Approved under the standard stated in the filing — “● Proposal 3 (Ratification of the Appointment of our Independent Registered Public Accounting Firm) requires the affirmative vote of the majority of the shares present in person or represented by proxy at the meeting and entit nary Voting Proposal 1 -- Election of Directors ​ The number of votes "for" a director must exceed the number of votes "against" a director ​ Abstentions and broker non-votes will not be considered in determining the outcome of the proposal ​ No Proposal 2 -- Advisory Vote to Approve Named Executive Officer Compensation ​ Affirmative vote of the majority of the shares present in person or represented by proxy at the meeting and entitled to vote on the subject matter ​ Abstentions will have the effect of votes "against" the proposal and broker non-votes will not be considered in determining the outcome of the proposal ​ No Proposal 3 -- Ratification of the Appointment of our Independent Reg ay direct the trustee how to vote your plan shares by submitting your proxy vote for those shares, along with the rest of your shares, by Internet, phone or mail, as described above.”.

b. Approved under the standard stated in the filing — “on of Directors ​ As this is an uncontested election, the number of votes for a director must exceed the number of votes against a director ​ Abstentions and broker non-votes will not be considered in determining the outcome of the proposal ​ No Proposal 2 -- Advisory Vote to Approve Named Executive Officer Compensation ​ Majority of the shares present and entitled to vote on the proposal in person or represented by proxy ​ Abstentions will have the effect of negative votes and broker non-votes will not be considered in determining the outcome of the proposal ​ No Proposal 3 -- Amend and Restate Our Articles to Add A Right for Shareholders to Call a Special Meeting propriate.”.

c. Approved under the standard stated in the filing — “on of Directors ​ As this is an uncontested election, the number of votes for a director must exceed the number of votes against a director ​ Abstentions and broker non-votes will not be considered in determining the outcome of the proposal ​ No Proposal 2 -- Advisory Vote to Approve Named Executive Officer Compensation ​ Majority of the shares present and entitled to vote on the proposal in person or represented by proxy ​ Abstentions will have the effect of negative votes and broker non-votes will not be considered in determining the outcome of the proposal ​ No Proposal 3 -- Amend and Restate Our Amended and Restated Articles of Incorporation to Eliminate Superma nter difficulties accessing the virtual meeting, please call the technical support number that will be posted at www.virtualshareholdermeeting.com/WST2024 .”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

Of the companies WEST PHARMACEUTICAL SERVICES INC names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including WEST PHARMACEUTICAL SERVICES INC.

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.